Article Summary
A published case report from the National Allergy Centre described the long-term follow-up of a 20-year-old man with severe, refractory, steroid-dependent atopic dermatitis (AD) together with rhinitis and asthma. His symptoms had begun at the age of four and had responded poorly to several conventional treatments, while oral corticosteroids provided symptomatic relief.
The case report evaluated combined House Dust Mite (HDM) subcutaneous allergen immunotherapy (SCIT) and the anti-IgE medicine omalizumab. The patient received the combined approach for three years and was then followed for a further two years after treatment cessation. The authors reported marked improvement in disease severity, quality of life, rhinitis and asthma control, together with reduced reliance on oral corticosteroids. They concluded that the approach appeared durable and well tolerated in this individual case, while emphasizing that larger controlled studies are needed.
Understanding Atopic Dermatitis
Atopic dermatitis is a common inflammatory skin disease involving both impairment of the skin barrier and abnormal immune responses. According to the case report, disruption of the epidermal barrier can increase the skin’s permeability to allergens, irritants and microbes.
The report notes that approximately 20% of patients with atopic dermatitis have moderate-to-severe disease. Severe disease can be associated with significant effects on quality of life, including sleep disruption, emotional or mental-health difficulties and interference with daily activities.
The Role of House Dust Mites
House dust mites are described in the report as important indoor allergen sources associated with allergic manifestations involving both the respiratory tract and the skin. Their allergens can interact with the skin barrier and immune system.
The report highlights Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df), two house dust mite species relevant to the patient’s sensitization. It also discusses Der p 11, a major allergen associated with atopic dermatitis.
The Patient’s Clinical Background
The case involved a 20-year-old man whose atopic dermatitis, rhinitis and asthma had started at the age of four. Conventional treatments had included topical corticosteroids, leukotriene inhibitors, antihistamines, courses of oral cyclosporin and oral corticosteroids. The patient’s symptoms were reported to worsen following exposure to dust and after ingestion of alcohol, peanuts and eggs.
Before the combined treatment, the patient had severe disease. His SCORAD score was 75/103, DLQI was 20/30, RCAT was 10/25, ACT was 11/25, and peak expiratory flow rate (PEFR) was 350 L/min. His total IgE level was reported as greater than 15,000 IU/mL.
Allergy Assessment
Skin prick testing was positive for Dermatophagoides pteronyssinus, Dermatophagoides farinae, cockroach, egg and peanut. Specific IgE was positive for D. pteronyssinus, D. farinae and cockroach.
The report also describes a consistent history of worsening symptoms after dust exposure, including aggravation of atopic dermatitis as well as sneezing, wheezing, cough and shortness of breath.
The Combined Treatment Approach
The patient received House Dust Mite subcutaneous allergen immunotherapy together with anti-IgE therapy using omalizumab. The report describes a gradual up-dosing protocol for HDM SCIT to reach a maintenance dose of 500 Allergy Units (AU). Omalizumab was used alongside the immunotherapy during the treatment period.
Supportive treatment was also continued, including moisturizing agents, topical steroids, antihistamines and a tapering dose of oral methylprednisolone. The combined treatment was continued for three years.
Reported Improvement
The case report describes substantial improvement in the patient’s clinical measurements. After treatment, the SCORAD score decreased from 75/103 to 10/103, indicating a marked reduction in the reported severity of atopic dermatitis.
The Dermatology Life Quality Index (DLQI) increased from 20/30 to 28/30, while the Rhinitis Control Assessment Test (RCAT) increased from 10/25 to 22/25 and the Asthma Control Test (ACT) increased from 11/25 to 23/25. PEFR increased from 350 L/min to 500 L/min.
The report also describes a reduction in oral corticosteroid use. Before treatment, the patient was using approximately 64 mg of methylprednisolone per month. At follow-up, the reported amount was approximately 8 mg per month.
Five-Year Follow-Up
One of the notable aspects of the case report is the follow-up period. The patient received combined HDM SCIT and omalizumab for three years and subsequently remained under follow-up for another two years after stopping the combined therapy.
The authors reported that disease control was maintained during the two years after cessation of the combined treatment. They described improvement in quality of life, disease severity and reduced side effects associated with oral corticosteroid use.
Why Is This Combination of Interest?
Omalizumab is an anti-IgE monoclonal antibody that binds free human IgE. The report discusses the potential for combining anti-IgE treatment with allergen immunotherapy to improve tolerability and allow patients to progress through immunotherapy dosing.
The authors also discuss existing evidence suggesting that allergen immunotherapy may benefit a subset of highly sensitized patients with atopic dermatitis, particularly when there is evidence that exposure to the relevant aeroallergen is associated with disease exacerbations. However, the report notes that evidence for allergen immunotherapy in atopic dermatitis remains mixed and that guidelines do not recommend it as a first-line treatment for all patients.
Key Takeaways
- Atopic dermatitis can occur alongside allergic rhinitis and asthma, creating a complex pattern of allergic disease.
- House dust mites are important indoor allergens and may be relevant to selected patients with allergic skin and respiratory disease.
- The reported patient had severe, refractory, steroid-dependent atopic dermatitis with rhinitis and asthma and demonstrated house dust mite sensitization.
- The case report describes treatment with HDM subcutaneous allergen immunotherapy combined with omalizumab for three years.
- The patient showed reported improvement in atopic dermatitis severity, quality of life, rhinitis control, asthma control and peak expiratory flow.
- The report describes continued disease control during a further two-year follow-up after the combined treatment was stopped.
- The authors emphasize that larger prospective controlled studies are required to verify the approach.
Important Note
This article is an educational summary of a published single-patient case report. The findings should not be interpreted as evidence that the combined treatment will have the same effect in all patients. Allergen immunotherapy and omalizumab require appropriate medical assessment and supervision. Treatment decisions should be made with a qualified healthcare professional.
Source
Kathuria PC, Rai M (2020). Successful Treatment by Combination Therapy of Omalizumab (Anti-IgE) and House Dust Mite Allergen Immunotherapy for Severe Refractory Steroid-Dependent Atopic Dermatitis with Rhinitis and Asthma – A Case Report-Follow Up for 5 Years. JSM Allergy Asthma, 4(1):1026.








